AT205670B - - Google Patents
Info
- Publication number
- AT205670B AT205670B AT651358A AT651358A AT205670B AT 205670 B AT205670 B AT 205670B AT 651358 A AT651358 A AT 651358A AT 651358 A AT651358 A AT 651358A AT 205670 B AT205670 B AT 205670B
- Authority
- AT
- Austria
- Prior art keywords
- oxyalkylated
- aminoalkylated
- sep
- mixtures
- water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 150000003212 purines Chemical class 0.000 claims description 5
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical class CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE205670T | 1956-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT205670B true AT205670B (en:Method) | 1959-10-10 |
Family
ID=29556987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT651358A AT205670B (en:Method) | 1956-05-17 | 1957-05-16 |
Country Status (1)
| Country | Link |
|---|---|
| AT (1) | AT205670B (en:Method) |
-
1957
- 1957-05-16 AT AT651358A patent/AT205670B/de active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69000645T2 (de) | Bei kuehlschranktemperatur stabile waessrige folinatloesung sowie verfahren zu deren herstellung. | |
| DE2501787C2 (en:Method) | ||
| DE2504331A1 (de) | Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung | |
| AT205670B (en:Method) | ||
| EP0023355B1 (de) | Arzneimittellösungen und Verfahren zu deren Herstellung | |
| AT205669B (en:Method) | ||
| DE3212909A1 (de) | 7-(2-diaethylaminoaethyl)-theophyllin-acetylsalicylat und verfahren zu seiner herstellung | |
| DE800413C (de) | Verfahren zur Herstellung neutraler Loesungen von Polyalkylxanthinen | |
| AT206587B (de) | Verfahren zur Herstellung von pharmazeutischen Präparaten, die oxyalkylierte Theophyllin- und bzw. oder oxyalkylierte Theobromverbindungen enthalten | |
| DE2521905C2 (de) | Arzneimittel zur cerebralen Durchblutungsförderung | |
| DE1151096B (de) | Verfahren zur Herstellung haltbarer, konzentrierter waessriger Loesungen von oxyalkylierten Theophyllin- oder oxy-alkylierten Theobrominverbindungen | |
| DE1154899B (de) | Verfahren zur Loeslichkeitserhoehung von Purinen und Purinderivaten | |
| DE967872C (de) | Verfahren zur Herstellung waessriger Loesungen von in Wasser schwer loeslichen Arzneimitteln | |
| DE925541C (de) | Verfahren zur Herstellung waessriger Loesungen von in Wasser schwer loeslichen Arzneimitteln | |
| DE762284C (de) | Verfahren zur Erhoehung der Wasserloeslichkeit der Dimethylxanthine und ihrer Verbindungen | |
| DE508334C (de) | Verfahren zur Herstellung halbarer Loesungen von Arsenobenzolen | |
| DE830955C (de) | Verfahren zur Herstellung bestaendiger Trinitroalkanolaminsalze | |
| DE2316269C2 (de) | Stabilisierung eines Herztherapeutikums auf der Basis von beta-Acetyldigoxin | |
| DE937373C (de) | Verfahren zur Herstellung waessriger Arzneimittel-Loesungen | |
| DE1046832B (de) | Verfahren zur Erhoehung der Lagerbestaendigkeit konzentrierter waessriger Adenosinloesungen | |
| AT149825B (de) | Verfahren zur Herstellung von Alkali- bzw. Erdalkalidoppelverbindungen der Dimethylxanthine mit organischen Säuren. | |
| DE951757C (de) | Verfahren zum Stabilisieren von Mutterkornalkaloiden | |
| AT117985B (de) | Verfahren zur Herstellung von Öllösungen therapeutisch anwendbarer Stoffe. | |
| AT99940B (de) | Verfahren zur Überführung wasserunlöslicher bzw. schwerlöslicher Arzneimittel in tropfbare und injizierbare Form. | |
| DE948153C (de) | Verfahren zur Herstellung des hoeherschmelzenden Isomeren des 2-AEthylcrotonylharnstoffes |